Capricor Therapeutics, Inc. (FRA:4LN2)
18.86
0.00 (0.00%)
At close: Feb 18, 2026
Capricor Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Cash & Equivalents | 19.51 | 11.29 | 14.69 | 9.6 | 34.89 | 32.67 |
Short-Term Investments | 79.06 | 140.23 | 24.79 | 31.82 | - | - |
Cash & Short-Term Investments | 98.57 | 151.52 | 39.49 | 41.42 | 34.89 | 32.67 |
Cash Growth | 15.92% | 283.70% | -4.67% | 18.74% | 6.79% | 230.45% |
Receivables | 0.06 | 10.37 | 10.37 | 0.55 | 0.39 | 0.06 |
Prepaid Expenses | 2.33 | 1.5 | 1 | 0.92 | 1.16 | 0.96 |
Total Current Assets | 100.95 | 163.39 | 50.86 | 42.89 | 36.44 | 33.68 |
Property, Plant & Equipment | 25 | 6.87 | 7.61 | 6.94 | 4.62 | 0.85 |
Other Intangible Assets | - | - | - | - | - | 0 |
Other Long-Term Assets | 0.49 | 0.22 | 0.27 | 0.27 | 0.28 | 0.09 |
Total Assets | 126.44 | 170.48 | 58.73 | 50.09 | 41.33 | 34.62 |
Accounts Payable | 2.72 | 8.18 | 6.24 | 4.83 | 3.12 | 2.72 |
Accrued Expenses | 9.93 | 0.01 | 0.01 | 0.09 | 0.6 | 0.01 |
Current Portion of Long-Term Debt | - | - | - | - | - | 0.25 |
Current Portion of Leases | 0.12 | 0.83 | 0.75 | 0.68 | 0.42 | - |
Current Unearned Revenue | 12 | 12 | 24.27 | 17.98 | - | - |
Other Current Liabilities | 3.38 | - | - | - | - | - |
Total Current Liabilities | 28.15 | 21.03 | 31.27 | 23.59 | 4.13 | 2.97 |
Long-Term Debt | - | - | - | - | - | 0.07 |
Long-Term Leases | 14.42 | 0.62 | 1.49 | 1.88 | 2.45 | - |
Long-Term Unearned Revenue | - | - | - | 9.47 | - | - |
Other Long-Term Liabilities | - | 3.38 | 3.38 | 3.38 | 3.38 | 3.38 |
Total Liabilities | 42.57 | 25.02 | 36.13 | 38.31 | 9.96 | 6.42 |
Common Stock | 0.05 | 0.05 | 0.03 | 0.03 | 0.02 | 0.02 |
Additional Paid-In Capital | 357.68 | 344.22 | 181.7 | 148.74 | 139.4 | 116.22 |
Retained Earnings | -274.71 | -199.83 | -159.37 | -137.08 | -108.06 | -88.04 |
Comprehensive Income & Other | 0.84 | 1.03 | 0.24 | 0.11 | - | - |
Shareholders' Equity | 83.87 | 145.46 | 22.6 | 11.79 | 31.37 | 28.2 |
Total Liabilities & Equity | 126.44 | 170.48 | 58.73 | 50.09 | 41.33 | 34.62 |
Total Debt | 14.54 | 1.45 | 2.24 | 2.56 | 2.87 | 0.32 |
Net Cash (Debt) | 84.02 | 150.06 | 37.25 | 38.86 | 32.01 | 32.35 |
Net Cash Growth | 0.77% | 302.84% | -4.14% | 21.38% | -1.03% | 227.23% |
Net Cash Per Share | 1.85 | 4.26 | 1.39 | 1.58 | 1.39 | 2.08 |
Filing Date Shares Outstanding | 45.72 | 45.68 | 31.4 | 25.26 | 24.3 | 22.8 |
Total Common Shares Outstanding | 45.72 | 45.58 | 31.15 | 25.24 | 24.19 | 20.58 |
Working Capital | 72.8 | 142.36 | 19.59 | 19.3 | 32.3 | 30.71 |
Book Value Per Share | 1.83 | 3.19 | 0.73 | 0.47 | 1.30 | 1.37 |
Tangible Book Value | 83.87 | 145.46 | 22.6 | 11.79 | 31.37 | 28.2 |
Tangible Book Value Per Share | 1.83 | 3.19 | 0.73 | 0.47 | 1.30 | 1.37 |
Machinery | 7.65 | 6.51 | 5.64 | 4.38 | 0.04 | 1.52 |
Leasehold Improvements | 2.79 | 2.5 | 2.13 | 1.39 | 2.51 | 0.05 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.